Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) ...

Receptor tyrosine kinases (RTKs) are a large group of integral membrane signaling molecules. Mutations in the RTK anaplastic lymphoma kinase (Alk) protein have been linked with non-Hodgkin lymphoma, ...

Results from the phase 3 INSPIRE study showed that treatment with Iruplinalkib reduced the risk of disease progression or death by 66% among patients with ALK-positive non-small cell lung cancer.